Journal
ATHEROSCLEROSIS
Volume 303, Issue -, Pages 8-14Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2020.03.014
Keywords
Dyslipidemias; Liver organoids; Regenerative medicine; Drug testing; Non-alcohol fatty liver disease
Funding
- Gilead Research scholarship grant
- Amsterdam UMC Fellowship
- Health-Holland TKI-PPP grant
- NIH [HL134853, DK114291-01A1]
Ask authors/readers for more resources
Dyslipidemias are strongly linked to the development of atherosclerotic cardiovascular disease. Most dyslipi- demias find their origin in the liver. In recent years, the differentiation of induced pluripotent stem cells (iPSCs) into hepatocyte-like cells has provided a versatile platform for the functional study of various dyslipidemias, both rare genetic dyslipidemia as well as common lipid disorders associated with insulin resistance or non- alcoholic fatty liver disease. In addition, iPSC-derived hepatocytes can serve as a cell model for developing novel lipid lowering therapies and have the potential of regenerative medicine. This review provides an overview of these developments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available